Prof. Ulf Landmesser, Zurich and prof. John Deanfield, London are talking about good and bad cholesterol; HDL being the good cholesterol for years to the public. HDL might not always be good cholesterol. A big distinction has to be made between using HDL as a risk marker and as a treatment target; HDL cholesterol alone cannot be the treatment target. Each HDL targeted therapy has to be very carefully looked at.
It has to be investigated how to improve the anti-atherogenic functions of HDL. The HDL metabolism is very complex; the correct target within that metabolism has to be identified. HDL thus becomes very important as a new form of treatment compared to just lowering LDL cholesterol with statins.
Topics discussed in this PACE talk:
Why is HDL not always the good cholesterol?
CETP as HDL-targeted therapy – is it safe?
What did you see in patients with coronary artery disease?
Is raising HDL always beneficial?
What is the most important information from dal-VESSEL?